IL279441B2 - History of n-converted tetrahydrothinopyridines and their uses - Google Patents

History of n-converted tetrahydrothinopyridines and their uses

Info

Publication number
IL279441B2
IL279441B2 IL279441A IL27944120A IL279441B2 IL 279441 B2 IL279441 B2 IL 279441B2 IL 279441 A IL279441 A IL 279441A IL 27944120 A IL27944120 A IL 27944120A IL 279441 B2 IL279441 B2 IL 279441B2
Authority
IL
Israel
Prior art keywords
core
mmol
cyano
tetrahydrothieno
methyl
Prior art date
Application number
IL279441A
Other languages
English (en)
Hebrew (he)
Other versions
IL279441A (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67841114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL279441(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL279441A publication Critical patent/IL279441A/en
Publication of IL279441B2 publication Critical patent/IL279441B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL279441A 2018-06-19 2019-06-18 History of n-converted tetrahydrothinopyridines and their uses IL279441B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687068P 2018-06-19 2018-06-19
PCT/IB2019/055121 WO2019244047A1 (en) 2018-06-19 2019-06-18 N-substituted tetrahydrothienopyridine derivatives and uses thereof

Publications (2)

Publication Number Publication Date
IL279441A IL279441A (en) 2021-01-31
IL279441B2 true IL279441B2 (en) 2023-06-01

Family

ID=67841114

Family Applications (1)

Application Number Title Priority Date Filing Date
IL279441A IL279441B2 (en) 2018-06-19 2019-06-18 History of n-converted tetrahydrothinopyridines and their uses

Country Status (24)

Country Link
US (3) US12012417B2 (https=)
EP (2) EP4169925B1 (https=)
JP (1) JP7328260B2 (https=)
KR (1) KR102835904B1 (https=)
CN (1) CN112313237A (https=)
AU (1) AU2019291488B2 (https=)
BR (1) BR112020025696A2 (https=)
CA (1) CA3100957A1 (https=)
CL (1) CL2020003248A1 (https=)
CR (1) CR20200618A (https=)
CU (1) CU20200100A7 (https=)
EA (1) EA202190046A1 (https=)
EC (1) ECSP20080995A (https=)
ES (2) ES3062606T3 (https=)
IL (1) IL279441B2 (https=)
JO (1) JOP20200326A1 (https=)
MA (1) MA52976A (https=)
MX (1) MX2020013852A (https=)
MY (1) MY201990A (https=)
PE (1) PE20210097A1 (https=)
PH (1) PH12020552185A1 (https=)
SA (1) SA520420809B1 (https=)
SG (1) SG11202012625PA (https=)
WO (1) WO2019244047A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3663299B1 (en) * 2017-08-01 2023-03-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic compound acting as ror gamma inhibitor
BR112020025696A2 (pt) 2018-06-19 2021-03-16 Novartis Ag Derivados de tetra-hidrotienopiridina n-substituída e usos dos mesmos
USD1006154S1 (en) * 2023-06-27 2023-11-28 Qiongfang Mao Cable crossover attachment
WO2025238553A1 (en) 2024-05-14 2025-11-20 Novartis Ag Dosing regimens for n-(3-cyano-5-(cyclohexylmethyl)-6,6-dimethyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-2-(4-sulfamoylphenyl)acetamide for use in treating or preventing a dengue virus disease or disorder
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807A (en) 1848-09-26 Brake fob cabs
US6344A (en) 1849-04-17 Driving-bobbin
US498178A (en) 1893-05-23 William valentine leonard
US4656A (en) 1846-07-24 Improvement in potato-plows
US8766A (en) 1852-02-24 Appabatus for lightening vessels
US54472A (en) 1866-05-01 Improved blacking-brush
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CA2252465C (en) 1996-04-23 2007-07-03 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
DK0966465T3 (da) 1997-03-14 2003-10-20 Vertex Pharma Inhibitorer af IMPDH-enzymer
CA2367017C (en) 1999-03-19 2009-05-26 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
DE60236428D1 (de) 2001-05-21 2010-07-01 Monsanto Technology Llc Etheramin-tenside enthaltende pestizidkonzentrate
US20030232994A1 (en) 2001-10-04 2003-12-18 Shao-Po Lu Bicyclic thiophene derivatives and combinatorial libraries thereof
CA2498399A1 (en) 2002-09-12 2004-03-25 Merck & Co., Inc. Method of treating diabetes and related conditions
US7138529B2 (en) * 2003-04-16 2006-11-21 Hoffmann-La Roche Inc. Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
GB0324653D0 (en) 2003-10-22 2003-11-26 Syngenta Participations Ag Fungicides
ES2309765T3 (es) 2004-05-28 2008-12-16 4Sc Ag Tetrahidropiridotiofenos.
AU2005272646A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
EP1851229A1 (en) 2005-02-09 2007-11-07 Nycomed GmbH Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
AU2006212179A1 (en) 2005-02-11 2006-08-17 4Sc Ag Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer
BRPI0610283A2 (pt) 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
US7714136B2 (en) 2005-05-25 2010-05-11 4Sc Ag Tetrahydropyridothiophenes
US7763728B2 (en) 2005-05-25 2010-07-27 4Sc Ag Tetrahydropyridothiophenes
US7932391B2 (en) 2005-09-08 2011-04-26 Zhejiang Hauhai Pharmaceutical Co., Ltd. Method for the preparation of clopidogrel and its analogues of methyl-tetrahydrothieno[3,2-C]pyridine acetate
WO2008020024A1 (en) 2006-08-16 2008-02-21 4Sc Ag Ntetrahydropyridothiophene derivatives for the treatment of cancer
WO2008020045A1 (en) 2006-08-16 2008-02-21 4Sc Ag Tetrahydrobenzothiophene derivatives
WO2008067222A1 (en) 2006-11-28 2008-06-05 Kalypsys, Inc. Heterocyclic modulators of tgr5
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
MX2011008988A (es) 2009-02-27 2011-12-16 Siga Technologies Inc Derivados de tienopiridina para el tratamiento y prevencion de infecciones por el virus del dengue.
US20130129677A1 (en) * 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
JP5701655B2 (ja) 2011-03-29 2015-04-15 奈良県 植物精油中のトロポロン類及び／又はフェノール類の金属錯体化方法
AP2014007595A0 (en) 2011-09-30 2014-04-30 Kineta Inc Anti-viral compounds
US10844051B2 (en) 2015-07-22 2020-11-24 The Royal Institution For The Advancement Of Learning/Mcgill University Substituted oxazoles for the treatment of cancer
CN108689987A (zh) * 2017-04-05 2018-10-23 浙江海正药业股份有限公司 一种磺胺类衍生物及其制备方法和用途
CN110753682B (zh) * 2017-05-22 2023-06-30 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
EP3663299B1 (en) 2017-08-01 2023-03-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic compound acting as ror gamma inhibitor
CN108191885B (zh) * 2018-01-29 2020-08-04 华东师范大学 一类哌啶并噻吩类小分子有机化合物及其应用
BR112020025696A2 (pt) 2018-06-19 2021-03-16 Novartis Ag Derivados de tetra-hidrotienopiridina n-substituída e usos dos mesmos

Also Published As

Publication number Publication date
CL2020003248A1 (es) 2021-07-09
KR102835904B1 (ko) 2025-07-22
MA52976A (fr) 2021-04-28
US20220073535A1 (en) 2022-03-10
EP4169925A3 (en) 2023-06-14
US20260070920A1 (en) 2026-03-12
CN112313237A (zh) 2021-02-02
CR20200618A (es) 2021-01-21
ES3062606T3 (en) 2026-04-13
JP7328260B2 (ja) 2023-08-16
SG11202012625PA (en) 2021-01-28
US12331060B2 (en) 2025-06-17
AU2019291488B2 (en) 2022-02-24
EP3810613A1 (en) 2021-04-28
JOP20200326A1 (ar) 2020-12-14
IL279441A (en) 2021-01-31
SA520420809B1 (ar) 2022-08-17
ES2941946T3 (es) 2023-05-26
JP2021529159A (ja) 2021-10-28
PE20210097A1 (es) 2021-01-12
MX2020013852A (es) 2021-05-27
AU2019291488A1 (en) 2021-02-04
EA202190046A1 (ru) 2021-03-24
KR20210022645A (ko) 2021-03-03
CU20200100A7 (es) 2021-08-06
MY201990A (en) 2024-03-27
BR112020025696A2 (pt) 2021-03-16
EP4169925B1 (en) 2025-11-19
EP3810613B1 (en) 2023-01-11
ECSP20080995A (es) 2021-02-26
WO2019244047A1 (en) 2019-12-26
PH12020552185A1 (en) 2021-06-07
CA3100957A1 (en) 2019-12-26
US20240352030A1 (en) 2024-10-24
EP4169925A2 (en) 2023-04-26
US12012417B2 (en) 2024-06-18

Similar Documents

Publication Publication Date Title
US12331060B2 (en) N-substituted tetrahydrothienopyridine derivatives and uses thereof
EP3692028B1 (en) Inhibiting ubiquitin specific peptidase 30
CN102711473B (zh) 布鲁顿酪氨酸激酶抑制剂
AU2018389145B2 (en) Exo-aza spiro inhibitors of menin-MLL interaction
EP3534901B1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
ES3057371T3 (en) Antagonists of the muscarinic acetylcholine receptor m4
TWI712598B (zh) 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
EP3558309B1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
CN115043836A (zh) 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
CN104650070A (zh) 二氢嘧啶类化合物及其在药物中的应用
EP4048399A1 (en) Inhibitors of trek (twik related k+ channels) channel function
RU2776476C2 (ru) N-замещенные производные тетрагидротиенопиридина и их применение
HK40041690B (en) N-substituted tetrahydrothienopyridine derivatives and uses thereof
HK40041690A (en) N-substituted tetrahydrothienopyridine derivatives and uses thereof
EA041825B1 (ru) N-замещенные производные тетрагидротиенопиридина и их применение
AU2023204968B2 (en) Novel isoindolinone derivative compounds as caspase inhibitors
WO2025129082A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2026002044A1 (zh) 含有硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的双功能蛋白降解剂及它们的应用
WO2025162225A1 (zh) 具有取代的戊二酰亚胺基异吲哚啉酮新颖骨架的化合物及其应用
BR112020006456B1 (pt) Compostos químicos, composição farmacêutica e seus usos para tratar uma infecção por vírus da hepatite b e para inibir o nível do antígeno hbe ou hbs em um hbsag de mamífero in vitro
HK40036033B (en) Inhibiting ubiquitin specific peptidase 30
HK40036033A (en) Inhibiting ubiquitin specific peptidase 30
HK40014595A (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4